Personalis And Tempus Expand Collaboration; Tempus Invests $36M By Exercising Warrants To Purchase 9.2M Shares Of Common Stock At An Average Price Of $2 And To Purchase 3.5M Additional Shares At a Price Of $5.07
Personalis And Tempus Expand Collaboration; Tempus Invests $36M By Exercising Warrants To Purchase 9.2M Shares Of Common Stock At An Average Price Of $2 And To Purchase 3.5M Additional Shares At a Price Of $5.07
Tempus invests $36 million by exercising warrants and purchasing additional shares
Tempus通过行权认股权和购买额外股份,投资了3600万美元。
Personalis, Inc. (NASDAQ:PSNL) and Tempus AI, Inc. (NASDAQ:TEM) announced today that the companies have expanded their commercial relationship. The companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the recent ASCO meeting. Tempus is serving as exclusive commercial partner for Personalis' ultra-sensitive tumor-informed MRD product for broad patient adoption in breast and lung cancers, and for immunotherapy monitoring across all solid tumors.
Personalis, Inc.(纳斯达克:PSNL)和Tempus AI, Inc.(纳斯达克:TEM)今天宣布,双方已扩大商业关系。 两家公司于2023年11月达成协议,合作推出超敏感MRD测试,并在最近的ASCO会议上启动了相关工作。 对于乳腺癌和肺癌的广泛患者采用,Tempus正作为Personalis超敏感肿瘤信息的MRD产品的独家商业合作伙伴,并广泛应用于所有固体肿瘤的免疫治疗监测。
Following positive reaction and exceptionally strong demand, the companies have agreed to accelerate their efforts, expanding under the following key terms:
由于反应积极且需求强劲,两家公司已同意加快推进工作,按以下关键条款进行扩展:
- Tempus to accelerate its commercialization efforts over the first two years
- Personalis to increase the quantity of patient samples it will accept over the corresponding period
- Tempus to invest approximately $36 million into Personalis
- Tempus在前两年内加快其商业化发展的步伐
- Personalis将在相应时期内增加接收患者样本的数量。
- Tempus将投资约3600万美元到Personalis中。
"We are pleased that our early access program is proceeding well and demand is strong," said Chris Hall, CEO of Personalis. "We believe the expansion of the relationship with Tempus will allow us to better capitalize on the opportunity."
Personalis的首席执行官Chris Hall表示:“我们很高兴我们的早期接触计划进展顺利且需求强劲。我们相信与Tempus扩大关系将使我们更好地利用这个机会。”
Under the agreement, Tempus agreed to exercise its existing warrants to purchase 9.2 million shares of common stock in accordance with their terms at an average purchase price of $2.00 and to purchase an additional 3.5 million shares of common stock at a price per share of $5.07, which was the last reported closing price of Personalis' common stock as reported on The Nasdaq Global Market on August 15, 2024, for a total investment of approximately $36 million in Personalis. As a result, Tempus will own approximately 19.3 percent of Personalis' outstanding common stock following the closing of the transactions.
根据协议,Tempus同意按照条款行使其现有的认股权,以平均购买价格为2.00美元购买920万股普通股,并以每股5.07美元的价格购买另外350万股普通股,这是Personalis'普通股的最后报告收盘价,报告于2024年8月15日在纳斯达克全球市场上。此项交易将使Tempus持有Personalis普通股总数约占流通股的19.3%。